Contribute Try STAT+ Today

Top of the morning to you, and a fine one, it is. Delicious cool breezes and clear, blue skies are enveloping the Pharmalot campus this morning. One would never know a stubborn pandemic is lurking outside. But it is. And so, we interrupt our usual greeting for a public service announcement: a vaccine is only a shot away. Now back to our regularly scheduled line up of brewing cups of stimulation and foraging for items of interest. And of course, serving up tidbits. Hope your day is productive and, as always, stay safe…

Biogen (BIIB) recently submitted a paper to JAMA that analyzed clinical trial results for its new Alzheimer’s drug, Aduhelm, but later withdrew the paper because the journal considered rejecting it unless edits were made, Axios reports. Biogen says “JAMA did not reject the publication. Biogen withdrew the publication from JAMA and decided to pursue other publication opportunities.” Drug makers almost always publish study results in a peer-reviewed journal before obtaining FDA approval, but Biogen still has not done so for Aduhelm.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment